Stanford spinout scoops $10M to advance real-time brain mapping platform

A Stanford University spinout that lists Johnson & Johnson ($JNJ), Novartis ($NVS) and Pfizer ($PFE) among its users has raised $10 million to further develop its real-time brain mapping platform. The company, Inscopix, will use the money to advance the hardware and software behind its platform, while simultaneously scaling up its operation to support the commercialization of the system.

Inscopix opened its doors in 2011 to refine and commercialize prototypes developed at Stanford. The resulting platform combines a miniature microscope designed to image calcium ion activity in the brains of freely moving animals with a data analysis package. In 2012, Inscopix made the platform available through an early-access program, leading to its use at a clutch of Big Pharma companies and renowned academic research centers.

Palo Alto, CA-based Inscopix has persuaded some leading lights of the West Coast tech scene of the potential of its approach, giving it the financial means to embark on the next stage of its evolution. Playground Ventures, a hardware startup incubator and investment fund set up by the creator of Google’s Android, led the round with support from AME Cloud Ventures and Floodgate Fund. The investors are hoping Inscopix will establish itself as a key enabler of neuroscience research.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

“Inscopix has built an incredible product ecosystem to-date, but we believe an even bigger opportunity exists to further develop core hardware and software infrastructure that drives forward the future for brain research,” Playground Venture Partner Mark Valdez said in a statement.

AME has a big-name founder of its own, Yahoo! co-founder Jerry Yang, and a small portfolio of life science companies on its books. Inscopix joins cancer testing outfit Color and robot-run lab player Transcriptic in the life science corner of AME’s portfolio. Floodgate is less active in life sciences, but has backed a clutch of healthcare startups. And it has invested in some notable tech companies, including Lyft, Twitch and Twitter.

Suggested Articles

Bayer CEO Werner Baumann stressed “less and less trust in society" for technology advances as a hurdle for pharma companies working on gene editing.

Kintai Therapeutics' anti-obesity candidate KTX-0200 showed sustained weight loss and improved glucose control and liver health in rodents.

The respiratory care company Vyaire Medical has brought on a new CEO, Gaurav Agarwal, following a year of new product launches.